Publications

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

Download PDF
Resource: Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

.

Related Articles

Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies

Link
High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq

Link